Radius Health (NASDAQ: RDUS) reported Q3 EPS of ($1.09), $0.19 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $27.6 million versus the consensus estimate of $25.42 million.

“I am very pleased with the continued strong trajectory of our launch and success in growing the U.S. anabolic osteoporosis market. Our financial guidance reflects our confidence in continuing to capture further market share gains for TYMLOS and expanding the osteoporosis anabolic market,” said Jesper Hoeiland, President and Chief Executive Officer of Radius.

“With our updated Phase 3 protocol for elacestrant, we are excited to have the opportunity to address a larger patient population with unmet needs. We are on track to deliver on this key milestone and initiate the study in the fourth quarter of this year,” said Dr. Charles Morris, Chief Medical Officer of Radius

GUIDANCE:

Radius Health sees FY2018 revenue of $95-98 million, versus the consensus of $94.69 million.

Radius Health sees FY2019 revenue of $155-175 million, versus the consensus of $166.66 million.

For earnings history and earnings-related data on Radius Health (RDUS) click here.